Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

113.50 -0.19 (-0.17%)
Streaming Delayed Price Updated: 1:48 PM EDT, Sep 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,213,908
Open 113.61
Bid (Size) 113.48 (4)
Ask (Size) 113.50 (4)
Prev. Close 113.69
Today's Range 112.70 - 114.01
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.57%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 High-Potential Growth Stocks You Shouldn't Overlook
These two growth stocks have plenty of room to run. 
Via The Motley Fool
Is Merck Stock a Buy?
There is mounting pressure on the company's most prized franchise. 
Via The Motley Fool

Performance

YTD
+0.23%
+0.23%
1 Month
-4.18%
-4.18%
3 Month
-11.26%
-11.26%
6 Month
-13.35%
-13.35%
1 Year
+10.68%
+10.68%

More News

Read More
Evaxion Biotech Partners With Merck To Expand Vaccine Development
Via Benzinga
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
From Merck & Co., Inc.
Via Business Wire
This Is What Whales Are Betting On Merck & Co
Via Benzinga
Merck & Co Unusual Options Activity For September 23
Via Benzinga
Exploring NYSE:MRK's dividend characteristics.
Via Chartmill
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
Via Benzinga
Exposures Product Safety
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Via Benzinga
Exposures Product Safety
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Via Benzinga
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
From Merck & Co., Inc.
Via Business Wire
NYSE:MRK: good value for what you're paying.
Via Chartmill
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
From Merck & Co., Inc.
Via Business Wire
Pfizer Advances On Its Cancer Journey
Via Benzinga
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
From Merck & Co., Inc.
Via Business Wire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Via FinancialNewsMedia
Is It Too Late to Buy ServiceNow Stock?
Via The Motley Fool
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Via Benzinga
Exposures Product Safety
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
Via The Motley Fool
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
From Merck & Co., Inc.
Via Business Wire
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.